320 Logue Ave
Mountain View, VA 94043
Cellecta’s primary aim is to develop advanced high-throughput RNAi and peptide technologies and their applications for the discovery and functional characterization of novel therapeutic targets and drugs. We offer highly customized contract research services using advanced lentiviral technology, including HT sequencing-based shRNA library screens; HT functional validation of shRNA; custom shRNA library construction; custom stable reporter, overproducer, or knockdown cell lines; and HT screening for bioactive peptides. With more than 6 years of experience in HT functional screening, our scientists have developed the most advanced technology available in collaboration with opinion leaders and with funding from nine NIH SBIR grants.